What question did this study set out to answer?

The aim was to assess the efficacy and safety of recombinant human thrombopoietin in increasing platelet counts during invasive procedures in patients with CLD-related thrombocytopenia.

July 30, 2026American Journal of HematologyOpen Access

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

View Full Paper

Ask AI

Bookmark

Authors

YHYifan HanNorth China University of Science and Technology NLNing LinNanning Normal University JXJinghang XuPeking University

Discussion

Member takes

Implication

Randomized trial evaluates rhTPO's effectiveness in increasing platelet counts during invasive procedures, indicating its potential benefits for patients with liver disease.

Key Points

The aim was to assess the efficacy and safety of recombinant human thrombopoietin in increasing platelet counts during invasive procedures in patients with CLD-related thrombocytopenia.
Multicenter, randomized (2:1), double-blind, placebo-controlled phase III trial.
120 adult Chinese patients with CLD-related thrombocytopenia (platelet count < 50 × 10^9/L) received rhTPO (n=80) or placebo (n=40) daily for 5 or 7 days.
Primary endpoint was the proportion of patients with sustained platelet counts ≥ 50 × 10^9/L before and after invasive procedures without needing emergency bleeding management.
85.0% of patients in the rhTPO group achieved the primary endpoint versus 12.5% in the placebo group (p < 0.0001).
Platelet counts ≥ 50 × 10^9/L were achieved preoperatively in 92.5% of rhTPO patients compared to 20.0% in placebo (p < 0.0001).
Platelet transfusion was avoided in 92.5% of rhTPO patients versus 25.0% of placebo patients (p < 0.0001).

Cite This Study

Han et al. (2026) studied this question.

synapsesocial.com/papers/6a6af51f60e2b924d3ea0db7 https://doi.org/10.1002/ajh.70444

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates rhTPO's effectiveness in increasing platelet counts during invasive procedures, indicating its potential benefits for patients with liver disease.

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

Discussion

Member takes

Implication

Key Points

Cite This Study

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider